Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVOMELA
- Development stage
- Approved
- Lead developer
- Assertio
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
EVOMELA is a Captisol-enabled, preservative-free formulation of the alkylating agent melphalan. Developed by CASI Pharmaceuticals in partnership with Acrotech Biopharma, it is administered intravenously for the treatment of patients with multiple myeloma. As a nitrogen mustard derivative, melphalan works by forming covalent bonds with DNA, leading to interstrand and intrastrand crosslinks that inhibit DNA replication and transcription. This mechanism is particularly effective against rapidly proliferating malignant cells. EVOMELA is specifically indicated as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation (ASCT) and for the palliative treatment of multiple myeloma when oral therapy is not appropriate.
- Brand names
- EVOMELA
- Other names
- Melphalan for Injectionmelphalan hydrochlorideCaptisol-enabled melphalan
02
Targets
DNA
Beyond the preview
Go deeper on EVOMELA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EVOMELA.